A reported case of Marburg virus infection in Uganda has triggered renewed health vigilance in East Africa, according to reports from L’Expression. While the World Health Organization (WHO) has not yet declared a new outbreak in the country, the detection follows a significant Marburg outbreak in neighboring Rwanda that began in September 2024.
Marburg virus disease (MVD) is a severe viral hemorrhagic fever with a case fatality rate that can reach up to 88%, according to the World Health Organization. The virus is transmitted to humans from fruit bats, specifically Rousettus aegyptiacus, and then spreads through human-to-human contact via direct contact with blood, secretions, organs, or other bodily fluids of infected people.
Uganda has a history of managing Marburg outbreaks, including a 2017 event in the Kween district that resulted in three confirmed cases and three deaths. Health officials in the region are currently prioritizing surveillance and contact tracing to determine if the reported case is an isolated incident or the start of a wider transmission chain.
What are the symptoms and risks of Marburg virus?
The incubation period for Marburg virus ranges from two to 21 days. According to the Centers for Disease Control and Prevention (CDC), the illness begins abruptly with high fever, severe headache, and intense malaise. Muscle aches and pains are common in the early stages of the infection.
By the third day, patients often develop severe watery diarrhea, abdominal pain, and nausea. This stage is frequently accompanied by extreme lethargy and a characteristic “ghost-like” appearance, marked by deep-set eyes and expressionless faces. Many patients also develop a non-itchy rash, most prominent on the chest, back, and stomach, between days two and seven of the illness.
The most critical phase occurs in the later stages when hemorrhagic manifestations appear. This includes bleeding from the nose, gums, and other mucosal membranes. Internal bleeding is also common, manifesting as blood in the vomit or stool. Severe cases lead to multi-organ failure and severe hemorrhagic shock, which is the primary cause of death.
How does the regional context increase the risk?
The detection of a case in Uganda is particularly concerning due to the ongoing situation in Rwanda. In September 2024, Rwanda reported its first-ever outbreak of Marburg virus, which primarily affected healthcare workers in Kigali. According to WHO situational reports, the Rwanda outbreak highlighted the high risk of nosocomial transmission—spread within healthcare settings—when strict infection prevention and control (IPC) measures are not maintained.
The proximity of Uganda to Rwanda increases the likelihood of cross-border transmission. Both countries share similar ecological environments that support the Rousettus aegyptiacus bat population, the natural reservoir for the virus. Public health experts monitor these “spillover” events, where the virus jumps from animals to humans, often occurring in people who enter caves or mines where these bats roost.
Comparing the Rwanda and Uganda contexts, the Rwanda outbreak was notable for its concentration in clinical settings, whereas previous Ugandan outbreaks have often been linked to community spread in rural districts. This difference necessitates a dual approach to surveillance: monitoring both rural wildlife interfaces and urban healthcare facilities.
Why is there no approved vaccine or cure?
Currently, there is no approved vaccine or antiviral treatment specifically for Marburg virus disease. Treatment is limited to supportive care, which focuses on maintaining fluid and electrolyte balance and treating specific symptoms as they arise. According to the WHO, early supportive care—such as rehydration with oral or intravenous fluids—significantly improves the chances of survival.
The lack of a licensed vaccine is due to the rarity of outbreaks. Because Marburg occurs sporadically and in small clusters, it is difficult to conduct the large-scale Phase III clinical trials required for regulatory approval. However, several vaccine candidates are currently in development. Some of these utilize viral vector platforms, similar to the technology used in some Ebola vaccines, to trigger an immune response against the Marburg glycoprotein.
The scientific challenge lies in the virus’s ability to suppress the host’s early immune response. Marburg virus interferes with the production of interferon, a critical protein that helps the body fight viral infections. This allows the virus to replicate rapidly before the immune system can mount an effective defense, often leading to the “cytokine storm” that causes systemic vascular leak and organ failure.
How do health authorities stop the spread?
Containment of Marburg virus relies on a rigorous public health strategy centered on three pillars: rapid detection, contact tracing, and safe burials.
Rapid detection involves the use of polymerase chain reaction (PCR) tests to confirm the presence of the virus in a patient’s blood. Because the symptoms of MVD overlap with other diseases common in the region, such as malaria, typhoid fever, and Ebola, laboratory confirmation is essential to prevent misdiagnosis and unnecessary exposure of healthcare workers.
Contact tracing requires health teams to identify every person who had direct contact with an infected individual. These contacts are monitored for 21 days—the maximum incubation period. If a contact develops a fever, they are immediately isolated to prevent further transmission.
Safe and Dignified Burials (SDBs) are a critical component of outbreak control. The bodies of deceased MVD patients remain highly infectious. Traditional burial practices that involve washing or touching the body can lead to “super-spreader” events. Specialized teams use personal protective equipment (PPE) to ensure the deceased are buried safely without compromising the dignity of the family or the deceased.
What happens next for Uganda?
Ugandan health authorities are expected to coordinate with the WHO and the Africa Centres for Disease Control and Prevention (Africa CDC) to verify the source of the reported infection. The primary objective is to determine if the case is an imported infection from a neighboring country or a primary spillover event from a local animal reservoir.
If the case is confirmed as part of a new cluster, the Ministry of Health will likely activate the National Task Force on Epidemics and Pandemics. This would involve deploying rapid response teams to the affected area to conduct community sensitization and strengthen screening at border crossings.
The next confirmed checkpoint will be the release of an official epidemiological report from the Uganda Ministry of Health or a formal situation update from the WHO Regional Office for Africa. These reports will clarify the number of confirmed cases, the number of contacts under monitoring, and whether the transmission chain has been broken.
We encourage readers to share this report to increase awareness of hemorrhagic fever symptoms and to follow official government health advisories. Please leave your questions or comments below.